Most Clicked BIO SmartBrief Stories


1. Ambrx to be purchased by WuXi, other firms

BIO SmartBrief | May 26, 2015

San Diego-based Ambrx will be acquired by a consortium that includes Wuxi PharmaTech. The acquisition, which is expected to be completed sometime in the next several weeks, will give WuXi access to Ambrx's antibody-drug conjugate technology and its biologics development expertise. BioPharmaReporter.com (05/22)


2. AbbVie wraps up purchase of Pharmacyclics for $21B

BIO SmartBrief | May 27, 2015

AbbVie's purchase of Pharmacyclics has been completed for $21 billion. The deal gives AbbVie access to Pharmacyclics' blood cancer drug Imbruvica. Pharmacyclics will operate in California as a unit of AbbVie. Chicago Sun-Times (free registration) (05/26)


3. European agency releases draft guidelines for gene therapies

BIO SmartBrief | May 26, 2015

The European Medicines Agency has released guidelines on the authorization of gene therapies. The recommendations include consideration of biological vectors, potential in vivo effects on nucleic acid sequences and the design of nonclinical trials. Regulatory Focus (05/21)


4. EU recommends approval of Merck's Keytruda for melanoma

BIO SmartBrief | May 26, 2015

The European Medicines Agency endorsed Merck's Keytruda, or pembrolizumab, for the treatment of advanced melanoma as a first-line therapy and in patients who received prior treatment. The drug has been approved in the U.S. Reuters (05/22)


5. J&J to seek regulatory approval for 10 drugs in next 4 years

BIO SmartBrief | May 22, 2015

Johnson & Johnson will submit at least 10 new drugs for review by 2019 and seek more than 40 expanded approvals for existing treatments. Each of the 10 potential new drugs could earn at least $1 billion annually, according to the company, and they include investigational treatments for psoriasis, multiple myeloma and rheumatoid arthritis. Many were developed with partners or licensed from other drugmakers. The Wichita Eagle (Kan.) (05/20) The Wall Street Journal (tiered subscription model) (05/20)


6. Boehringer signs antibody-drug-development deal with Eureka

BIO SmartBrief | May 22, 2015

Boehringer Ingelheim agreed to collaborate with Eureka Therapeutics to discover and develop new therapeutic antibody treatments for cancer using Eureka's technology. Eureka is entitled to receive undisclosed payments, including an upfront fee, research funding and fees related to technical success. PharmaTimes (U.K.) (05/21)


7. House panel OKs 21st Century Cures measure

BIO SmartBrief | May 22, 2015

The 21st Century Cures bill passed the House Energy and Commerce Committee in a 51-0 vote Thursday. The bill would speed up drug approval by requiring the FDA to improve its drug review process, look at more flexible forms of clinical studies and include patient experience in the decision-making process. The full House is expected to vote on the measure in June. The Hill (05/21) Reuters (05/21)


8. Aspen sells unit to Strides Arcolab Limited

BIO SmartBrief | May 22, 2015

Aspen Pharmacare's Australian unit will be acquired by Strides Arcolab Limited in a deal worth about $300 million. Under the terms of the agreement, Stride will gain access to Aspen's branded drugs as well as products that are in development, including several set to launch this year. The deal is expected to be completed in the second quarter. BioSpace (San Francisco) (05/21)


9. Biotech food technology is safe and can help address world hunger

BIO SmartBrief | May 22, 2015

The genome-editing technology CRISPR-Cas9, which can alter a specific gene and replace it with a better sequence, can potentially address the growing demand for food production, writes Tom Parrett. The tool can be used to modify a plant's DNA to produce a crop that is more nutritious, more adaptable and has greater yield, Parrett writes. However, despite the benefits and proven safety of biotech crops, activists in some countries are trying to block their use, preventing people who are in need of food from getting it, Parrett writes. Newsweek (05/21)


10. Consumers become wary of organic brands from Big Food

BIO SmartBrief | May 27, 2015

Large food companies are experiencing consumer trust issues with their organic brands due to the outcry in social media against biotech foods and corporate ownership, Paula Rosenblum writes. Experts say consumers are less likely to trust conglomerates, and once-popular organic brands can simply become "part of the mix" under their ownership. Forbes (05/26)




Sign up for BIO SmartBrief



Designed specifically for biotechnology industry professionals like you, BIO SmartBrief is a FREE daily e-mail newsletter. It provides the latest news and information you need to stay informed about important biotech issues. Learn more